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Abstract
Background: The term “position effect” is used when the expression of a gene is deleteriously affected by an
alteration in its chromosomal environment even though the integrity of the protein coding sequences is
maintained. We describe a patient affected by epilepsy and severe neurodevelopment delay carrying a balanced
translocation t(15;16)(p11.2;q12.1)dn that we assume caused a position effect as a result of the accidental
juxtaposition of heterochromatin in the euchromatic region.
Results: FISH mapped the translocation breakpoints (bkps) to 15p11.2 within satellite III and the 16q12.1
euchromatic band within the ITFG1 gene. The expression of the genes located on both sides of the translocation
were tested by means of real-time PCR and three, all located on der(16), were found to be variously perturbed: the
euchromatic gene NETO2/BTCL2 was silenced, whereas VPS35 and SHCBP1, located within the major
heterochromatic block of chromosome 16q11.2, were over-expressed. Pyrosequencing and chromatin
immunoprecipitation of NETO2/BTCL2 and VPS35 confirmed the expression findings. Interphase FISH analysis
showed that der(16) localised to regions occupied by the beta satellite heterochromatic blocks more frequently
than der(15).
Conclusions: To the best of our knowledge, this is the first report of a heterochromatic position effect in humans
caused by the juxtaposition of euchromatin/heterochromatin as a result of chromosomal rearrangement. The
overall results are fully in keeping with the observations in Drosophila and suggest the occurrence of a human
heterochromatin position effect associated with the nuclear repositioning of the der(16) and its causative role in
the patient’s syndromic phenotype.
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Background
Patients with syndromic clinical phenotypes include an
interesting subset of carriers of de novo balanced chro-
mosomal rearrangements with no apparent loss or gain
of genetic material. These abnormalities can be
explained by the loss of function of a dose-sensitive
gene disrupted by one rearrangement breakpoint [1-3].
The breakpoints of the balanced chromosomal rearran-
gements associated with a clinical phenotype are often
molecularly mapped in an attempt to identify the dis-
ease-causing genes affected by the abnormality.
Although the rearrangements may lead to the direct dis-
ruption of one or two genes, this is not always the case.
It has also been shown that breakpoints occur outside
the genes themselves and affect their regulation by caus-
ing a change in their position within the genome, a phe-
nomenon known as the “position effect” (PE).
Investigations of the PE have required intensive experi-
mental effort because of the unique features of each
case and the often scarcely defined length of the
involved genomic region.
A number of potential mechanisms can be suggested
to explain the position effects of chromosomal rearran-
gements in humans for a review see ref. [4]: 1) the
separation of a gene from its enhancer, promoter or
locus control region; 2) juxtaposition to an enhancer
element from another gene; 3) the removal of the long-
range insulator or boundary elements; 4) competition
with another enhancer; 5) alterations in local chromatin
structure; 6) alterations in nuclear organisation [5,6];
and 7) position effect variegation (PEV), when the genes
are moved into close proximity to constitutive hetero-
chromatin and their activity become unstable and leads
to variegated patches of gene expression.
PEV was first observed in Drosophila and was so
named because of the variegated pattern of expression
of euchromatic genes transposed to locations near to
pericentric heterochromatin as a result of natural or
induced genetic rearrangements [7-10]. The chromoso-
mal position effect can spread over distances of 1 Mb or
more, and generally reflects a gradient of gene inactiva-
tion that is inversely correlated with distance [10],
although it can also be affected by the local context of a
gene [11].
Some genes are specifically adapted to be expressed
exclusively in a heterochromatic context (heterochro-
matic genes) [9]. They are also influenced by PEV, but
their behaviour is opposite to that of genes located in
euchromatic chromosomal regions (euchromatic genes).
The regulatory implication of genes residing in hetero-
chromatic regions was first evidenced in a pioneering
study that linked PEV to euchromatic/heterochromatic
rearrangements: the variegation of the light gene, known
as Dmel\lt, encoding a protein containing a zinc ion
binding domain and residing at the heterochromatin
side of the rearrangement breakpoint, was enhanced by
an increased dose of Y chromosome constitutive hetero-
chromatin, whereas the variegation of genes located on
the euchromatic side of the breakpoint was suppressed
[12]. Subsequently, it was found that a number of other
heterochromatic genes show similar heterochromatic
dependence [13-15], some of which are unique in terms
of function and protein coding [16].
Sequencing projects have led to the discovery of hun-
dreds of heterochromatic genes in Drosophila, plants
and mammals, but no variegation effects have yet been
reported in humans, although they have been observed
in transgenic mice bearing incomplete functional gene
domains that became inserted into heterochromatic
regions [17].
Given the variability of chromosomal rearrangements,
rare patients carrying unique chromosomal abnormal-
ities often show single or multiple clinical signs that
cannot be assigned to any recognisable syndrome. We
here describe the molecular cytogenetic, genetic and epi-
genetic characterisation of a “private” balanced chromo-
somal translocation t(15;16)(p11.2;q12.1)dn carried by a
patient affected by epilepsy and severe neurodevelop-
ment delay. Fluorescence in situ hybridisation (FISH)
breakpoint mapping and analyses of the quantitative
expression and promoter epigenetic signatures of the
genes at or near the breakpoints showed that a simple
chromosomal rearrangement may involve multiple genes




The proband is the first and only daughter of healthy
and unrelated parents, and was born in the 39th g.w.
after an uncomplicated pregnancy with a birthweight of
3480 g (50th centile), a length of 50 cm (50th centile),
and a head circumference of 33.5 cm (10th centile). At
birth, she was affected by neonatal respiratory distress
and hypotonia.
During her first day of life, she experienced brief par-
tial seizures with secondary generalisation that were
treated with phenobarbital (PB) but recurred several
times a week until she was two months old, when they
started appearing as clusters of infantile axial spasms.
The spasms disappeared after treatment with valproic
acid (VPA), and the baby started to smile and gained
control of her head. At the age of six months, the
spasms returned and became daily until she was 30
months old, despite the administration of adrenocortico-
tropin hormone (ACTH) and gamma-vinyl GABA
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(GVG). Interictal electroencephalography (EEG) revealed
the presence of frequent paroxysms involving the tem-
poro-parietal regions of both hemispheres, with left pre-
dominance in the absence of a hypsarrhythmic pattern.
Subsequently, the spasms became progressively less
frequent with VPA treatment, occurring only a few
times a month during sleep or upon awakening. They
finally disappeared when the patient was five years old,
and interictal EEG revealed normal findings during
wakefulness and rare focal spikes on the parietal regions
only during sleep.
From the age of four years, the patient’s clinical pic-
ture progressively improved. Now aged 12 years, she can
sit alone, has hypotonic-dystonic cerebral palsy, is aver-
bal, and suffers from very severe cognitive impairment,
but her relationships are relatively good.
Cerebral MRI at the age of three years revealed a left
temporo-parietal focal abnormality suggesting a prenatal
insult with micropolygyria.
A physical examination at the age of 10 years showed
a length of 120 cm (< 3rd centile), a weight of 20 kg (<
3rd centile), and a head circumference of 49 cm (< 3rd
centile), together with brachyplagiocephaly, wide palpeb-
ral fissures with mild lateral ectropion and long eye-
lashes, thin fingers, and severe thoracic scoliosis.
The patient was originally referred to our laboratory
because of suspected Angelman syndrome, which was
ruled out as SNRPN methylation analysis showed a
biparental pattern and no UBE3A gene mutation was
found. Rett syndrome was ruled out by means of muta-
tion screening of the MeCp2 and CDKL5 genes.
Translocation breakpoints analysis
Karyotype analysis showed a balanced translocation t
(15;16)(p11.2;q12.1)dn.
FISH characterisation narrowed the 15p breakpoint
region to within 15p11.2 satellite III (D15Z1) on the
basis of the fact that probe D15Z1 gave a signal on both
derivative chromosomes 15 and 16 (Figures 1A and 1D),
whereas RPC1-98 C19 and RPC1-21I10 (containing beta
satellite sequences) only gave a signal on der(16) (Fig-
ures 1A and 1D), as did the rDNA probe RPC5-1174A5
(Figures 1B and 1D). As expected, the a-satellite probes
D15Z3 and D15Z4 gave a signal on the centromere of
der(15) (Figures 1C and 1D).
The 16q translocation bkp was mapped to 16q12.1
using a BAC contig and was localised within the ITFG1
gene, which is disrupted: the contiguous BACs showed
different hybridisation patterns, with CTD-3056I17 only
giving a signal on der(16) (Figure 1E), CTD-2027D24
giving a signal on both derivative chromosomes (Figure
1F), and RP11-474B12 giving a signal only on der(15)
(data not shown). In order to refine the localisation of
the 16q breakpoint, a 7 kb long-range PCR genomic
fragment, covering the distal part of IVS12, was hybri-
dised with patient metaphases. This probe only gave a
signal on der(16), the intensity of which was comparable
with that of the normal chromosome 16, thus allowing
the bkp region to be approximately narrowed to a 12 kb
interval (chr16:47268711-47280772, hg19) (Figure 1G
and 1H). All of the probes and the FISH results are
shown in Additional file 1: Table S1.
In order to investigate whether the translocation
involving the 15p heterochromatic blocks favoured a re-
localisation of the 16q euchromatic bkp regions in a het-
erochromatic environment, we performed tripled i-FISH
Figure 1 FISH mapping of the 15p bkp (A, B, C, D). A) The
D15Z1 satellite III probe targeting the 15p bkp gave a signal (green)
on both derivative chromosomes 15 and 16 (arrowed); the beta
satellite probe (RPC1-98 C19) gave a signal (blue) only on der(16)
(arrowed); and the GABRB3 probe targeted both 15q chromosomes
(red). B) The rDNA probe gave a signal on der(16). C) FISH of a-
satellite D15Z3 (green) and D15Z4 (red) probes. D) Ideograms
showing schematic FISH results concerning both derivative
chromosomes of t(15;16) in comparison with normal chromosomes
15 (left) and 16 (in yellow on right). The red circle represents the
NOR probe signals, the purple circle the beta satellite signals, the
blue circle the satellite III signals, and the red and green circles
(merged to yellow) the alpha satellite probe signals. FISH
characterisation of the 16q bkp (E, F, G, H). E) The CTD-3056I17
probe only gave a signal on der(16); F) The CTD-2027D24 probe
gave a signal on both derivative chromosomes; G) The long-range
PCR probe gave a signal only on der(16); H) Physical map of
chromosome 16q containing the bkp: the red arrows point to the
bkp region. The scale refers to the February 2009 human draft
sequence (hg19) from the UCSC genome browser.
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experiments using patient lymphoblast cells derived
from three different cultures and hybridised with probes
D15Z1, GABRB3 and RPC1-98 C19. For each experi-
ment, at least 100 nuclei were analysed by evaluating
the co-localisation of the 16q bkps with regions recog-
nised by the probe RPC1-98 C19, which contains beta-
satellite DNA.
We observed der(16) co-localisation with heterochro-
matic regions more frequently than der(15) co-localisa-
tion in all of the experiments (Figure 2).
Array CGH analysis
The analysis excluded the gain or loss of any genomic
region encompassing the der(15)/der(16) breakpoints
and flanking regions, including the loci monitored for
gene expression. It also revealed a loss on chromosome
9 and a gain on the X chromosome, neither of which
were listed in the reference Database of Genomic
Variants http://projects.tcag.ca/variation, a catalogue of
structural variations identified in healthy subjects. In
detail, high-resolution a-CGH analysis identified a pater-
nal deletion of at least 28 kb at 9p24.1 (chr9:6,215,819-
6,244,723, hg19) and a maternal duplication of at least
500 kb at Xp22.2 (chrX:11,686,237-12,187,337, hg19)
(Additional file 2: Figure S1). Two genes, MSL3 and
RFMPD4/PDZD10 map to Xp22.2, the latter covering a
duplication bkp and hence being hypothetically inter-
rupted. The 9p deletion disrupts the IL33 gene.
XCI pattern
In order to verify whether the maternally derived CNV
localised on chromosome X could be involved in the
patient’s phenotype, X chromosome inactivation assay
was performed analysing AR and DXS6673E loci. While
the AR locus was uninformative, the DXS6673e locus
displayed a random X inactivation in the mother (59:41)
whereas the patient showed a preferential X inactivation
of the maternal allele (82:18; Additional file 3: Figure
S2). These results indicate no role of this CNV in the
patient phenotype.
Gene expression
Real-time PCR using primers positioned on the opposite
sides of the bkp within ITFG1 IVS12 asses that the
amount of the 5’ portion of the transcript was compar-
able with that of the control and half that of its 3’ por-
tion, thus confirming the FISH results (Figure 3).
Given the complex syndromic phenotype of the
patient, we tested whether the breakage and juxtaposi-
tion of 15p constitutive heterochromatin to the 16q12.1
euchromatic region disturbed the expression of the
Figure 2 Nuclear position of derivative chromosomes with
beta satellite regions. i-FISH (top) performed using D15Z1 (green),
GABRB3 (red) and RPC1-98 C19 (blue) containing beta-satellite DNA.
The large and small arrows respectively indicate der(16) and der(15).
Chromosome 15 is not shown but it occupies the region in which
all three hybridization signals are located, with the green signal
larger than those identified on the two derivatives. At the bottom
left a drawing showing the expected hybridization pattern allowing
to recognize the three different chromosomes (der (16), der (15)
and chromosome 15) on nucleus. The picture above shows only the
expected pattern of hybridization on the three chromosomes in the
drawing below is also shown acrocentric regions recognized by the
probe containing beta-satellite DNA. At the bottom right graphs A,
B, and C show the rate of co-localisation of der(16) (dark grey) and
der(15) (light grey) to the regions targeted by the beta satellite. The
results average of three experiments is shown on the right.
Figure 3 Real-time quantitative PCR showing the relative
quantification (RQ) of ITFG1 cDNA amplification product
obtained using ex-18 primers, which was found to be half that
obtained using ex-3 primers. The expected ΔΔCt ratio is ≅1 when
both alleles are expressed, and 0.5 when only one allele is
expressed. The genes are indicated on the abscissa and the average
of three recorded expression levels on the ordinate. The grey and
white bars respectively represent the case and control.
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intact genes flanking the 16q bkp. We first analysed four
genes whose expression profiles and functions suggested
a possible causative role: VPS35 and NETO2/BTCL2,
which respectively map to 16q11.2 heterochromatic and
16q12.1 euchromatic bands, and are localised 0.5 Mb
and 62 kb from the bkp on der(16), and SIAH1 and
CBLN1, which both map to 16q12.1 and are localised
1.1 Mb and 2 Mb from the bkp on der(15). Real-time
PCR revealed halved expression of NETO2/BTCL2 and
the over-expression of VPS35, both located on der(16),
whereas the expression of SIAH1 was comparable with
that of the control (Figure 3). The expression of the
brain-specific CBLN1 gene was not quantifiable because
it was low in all of lymphoblast cell lines.
In order to establish whether other more distant genes
were transcriptionally perturbed, we also analysed the
expression of the der(16) genes lying at distances from
bkp of 1 Mb (SHCBP1), 0.56 Mb (ORC6L), 0.67 Mb
(GPT2) and 0.27 Mb (DNA JA2); SHCBP1 and ORC6L
are located in the major heterochromatic block of chro-
mosome 16 (16q11.2), and GPT2 and DNA JA2 in the
euchromatic band 16q12.1. We also monitored the
expression of the following genes located on der(15) at
16q12.1: ABCC12 (0.9 Mb from the bkp), N4BP1 (1.4
Mb), ADCY7 (3 Mb), BRD7 (3.1 Mb), CYLD (3.5 Mb),
SALL1 (3.9 Mb) RBL2 (6.2 Mb), HERPUD (9.7 Mb) and
CKLF (19 Mb). Only the SHCBP1 gene was expressed at
higher levels than the control levels (Figure 3), whereas
the expression of most of the genes (DNA JA2, ADCY7,
BRD7, CYLD and RBL2) was comparable with that of
the controls (data non shown). In relation to the
remaining genes (ORC6L, ABCC12, N4BP1, SALL1,
HERPUD and CKLF), we could not draw any conclu-
sions because of their low level of expression in the lym-
phoblast cell lines or the variability of expression in the
control samples (GPT2).
Epigenetic characterisation of the promoter regions
It is well known that H3mK9, H3mK27 and CpG site
methylation occurs in silenced gene promoters,
whereas the acetylation of histones H3 and H4 and H3
lysine 4 methylation correlate with transcriptionally
active genes. In order to assess the epigenetic status of
the intact genes flanking both sides of the 16q break-
point, lymphoblastoid cell lines from the patient and
controls were investigated for their DNA methylation
status and chromatin modifications in the regulatory
regions of the genes whose expression was disturbed
or slightly perturbed. In particular, we tested the pro-
moter regions of the NETO2/BTCL2, SIAH1, CYLD
and RBL2 genes.
The promoter methylation analysis was made using a
pyrosequencing assay that quantitatively measures the
methylation of all CpG sites. In the normal samples,
NETO2/BTCL2, SIAH1, CYLD and RBL2 were demethy-
lated at all of the analysed CpG sites; in the patient, and
in line with the gene expression results, we found a
NETO2 promoter methylation pattern indicating the
epigenetic silencing of one allele (mean 50% methyla-
tion) (Figure 4), whereas all of the other gene promoters
located on der(15) (SIAH1, CYLD and RBL2) showed a
methylation pattern comparable with that of the normal
samples (Figure 4).
We then tested seven different modifications on the
histone tails: H3, H4 acetylation, and H3 di- and tri-
methylation on lysine 4 (associated with an active chro-
matin state), and H3 di- and tri-methylation on lysine 9
and H3 di-methylation on lysine 27, which are specific
for transcriptionally silenced chromatin. The ChIP
assays showed H3 K9 di- and tri-methylation and H3
K27 di-methylation in the NETO2/BTCL2 promoter
(Additional file 4: Table S2), whereas VPS35 and SIAH1
showed the same qualitative histone code as the control.
As VPS35 was up-regulated, we used Real-time PCR on
chromatin immunoprecipitates to assess the quantitative
changes in the epigenetic modifications related to the
trascriptionally competent chromatin, and found
increased H4 acetylation and H3 tri-methylation on
lysine 4 (Figure 5).
Discussion
We believe that this may be the first description of a
human disease involving a heterochromatic PE, by
means of which intact euchromatic and heterochromatic
genes are respectively silenced or enhanced as a result
of euchromatin/heterochromatin juxtaposition to consti-
tutive heterochromatin. Although our molecular analysis
could not assay variegation in the classical sense of PEV,
at least three genes showed perturbed expression and
behaviour equivalent to that of Drosophila genes in the
same chromosomal context [8]. As in Drosophila, we
found the over-expression of heterochromatic genes
(VPS35 and SHCBP1) located at 16q11.2, and the
under-expression of the euchromatic gene (NETO2/
BTCL2) located at 16q12.1. In keeping with the expres-
sion results and the findings observed in Drosophila
[18], the silenced NETO2/BTCL2 “euchromatic” gene on
der(16) showed promoter DNA methylation and H3 K9
di- and tri-methylation/H3 K27 di-methylation histone
modifications, whereas the over-expressed VPS35 “het-
erochromatic” gene showed an increase in H4 acetyla-
tion and H3 tri-methylation on lysine 4 in comparison
with the control. These findings confirm that these
chromatin modifications act as universal markers of
active/inactive genes in both the heterochromatic and
euchromatic bands [18]. We did not observe any epige-
netic silencing of the assayed der(15) genes SIAH1,
CYLD and RBL2.
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The expression profiles and epigenetic findings consis-
tently revealed the presence of an alteration only on one
side of the translocation breakpoint, on the der(16)
chromosome. Interestingly but reasonably expected, we
also observed that der(16), owning chromosome 15
satellites, is more frequently associated with acrocentric
chromosomes beta satellite heterochromatic blocks than
der(15). In line with the results of recent studies leading
Figure 4 Pyrograms indicating the percentage of methylation of positions 20 CpG and 14 CpG within the NETO2 and SIAH1 promoter
regions in the patient (PZ) and normal lymphoblast cell lines (CTRL). The mean methylation percentages are shown in brackets.
Finelli et al. Molecular Cytogenetics 2012, 5:16
http://www.molecularcytogenetics.org/content/5/1/16
Page 6 of 10
to the conclusion that the reorganisation of chromoso-
mal territories may be an important step in the process
of gene silencing [6], our overall findings suggest that
the different behaviour of the two derivative chromo-
somes may be caused by the different nuclear re-locali-
sation of der(16).
Treatment with VPA, acting also as HDAC inhibitor,
could modify the epigenetic profile of the patient
[19,20], nevertheless the epigenetic signature observed
in the derivative chromosomes is coherent with a PE
mechanism and not altogether justifiable by the drug
treatment.
In terms of genotype-phenotype correlations, our
assumption is that most of the observed clinical signs of
our patient can be attributed to the de novo balanced
translocation. The clinical phenotype of the patient can
be interpreted as an effect of the disruption of the
ITFG1 gene combined with the heterochromatic PE
effect (assuming that the genes in question are dose
sensitive).
The 16q translocation bkp disrupts the ITFG1 gene
(an inhibitory regulator of PP2A that plays a role in
modulating kinase levels in the ATM/ATR signalling
pathway), leading to a truncated transcript that is not
degraded by nonsense-mediated RNA decay [21]. More-
over, some of the perturbed genes can be plausibly con-
sidered causative candidates on the basis of their
expression profiles and functions. These include
NETO2/BTCL2, which is highly expressed in fetal brain
and may play a role in the development and/or mainte-
nance of neuronal circuitry [22,23] as a similar gene in
rats encodes a protein that modulates glutamate signal-
ling in the brain by regulating kainate receptor function
[24,25]. The over-expressed VPS35 is also highly
expressed in the brain, and encodes an essential compo-
nent of the retromer complex [26,27]. The investigation
of other plausible candidates (e.g. CBLN1) was pre-
cluded by their lack of expression in lymphoblastoid cell
lines.
The imbalance in the X chromosome inherited from
the patient mother could contribute to the patient’s phe-
notype as it contains MSL3 gene and RFMPD4/PDZD10
gene, acting respectively as chromatin remodelling/tran-
scription regulating factor [28,29] and as positive regula-
tor of dendritic spine morphogenesis, with a role in the
maintenance of excitatory synaptic transmission [30]
Nonetheless, the X inactivation analysis showed a ran-
dom X inactivation in the mother and a preferential
maternal X inactivation in the daughter, excluding a
role for this CNV in the patient’s phenotype.
Conclusion
Our results, which were obtained from genetic and epi-
genetic studies, suggest the occurrence in human of the
PE due to an euchromatin/constitutive heterochromatin
juxtaposition. To our knowledge this is the first report
of a human disease involving this kind of PE
mechanism.
Despite our extensive characterisation, the multiple
genes that may be involved prevent a full understanding
of the pathogenetic mechanism. However, we can rea-
sonably assume that the heterochromatic PE in our case
leads to a situation that is comparable with that
observed in contiguous gene syndromes. Other carriers
of balanced translocations with a breakpoint in hetero-
chromatic sequences need to be similarly studied in
order to be able to generalise the contribution of hetero-
chromatic PE to human pathology.
Materials and methods
Cytogenetic and FISH analyses
QFQ-banded metaphases prepared from peripheral
blood lymphocytes using standard procedures were ana-
lysed, and their karyotype was described in accordance
with ISCN (2009) [31]. The probes used for the FISH
characterisation of the 15p bkp were the RPC1-98 C19
and RPC1-21I10 clones, provided by Invitrogene (cat. N.
RPCI1.C), both containing beta-satellite DNA and tar-
geting 15p11 and 15p13 heterochromatic bands [32]; the
RP5-1174A5 clone, which contains the DNA/rRNA cod-
ing sequences (NOR regions) http://www.biologia.uniba.
it/rmc/5-alfoidi/dJ1174A5.html has been selected from
RPCI-5 PACs library provided by the YAC Screening
Centre (Dibit, HSR, Milan, Italy); the D15Z1 satellite III
probe mixed with the GABRB3 probe (Abbott, cat N. 05
J22-015); and the pMC15 (D15Z3) and pTRA25
(D15Z4) clones containing specific chromosome 15
alpha satellite sequences [33] were kindly provided by
Prof. Mariano Rocchi, University of Bari. The contigu-
ous BACs, belonging to the RPCI-11 and the CTD
libraries and used for the FISH characterisation of the
16q bkp, were selected using the UCSC Genome Brow-
ser (http://genome.ucsc.edu/, hg19) and provided by
Figure 5 Real-time quantitative PCR of the immunoprecipitated
chromatin VPS35 promoter. The results of two independent
experiments.
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Prof. Mariano Rocchi (RPCI-11 clones) and by Invitro-
gene (CITB Human D BAC clones, cat. N. 96012D) The
16p bkp was also characterised by means of a 7 kb
probe covering part of ITFG1 intron 12, which was con-
structed by means of long-range PCR using the Expand
20KBPLUS PCR System (Roche, cat N. 11811002001) as
previously described [34]. The primer pair (fw 5-
GGCACCATCTTGGCACACTGCAACCTC3- and rev
5-ATTAGGAACCAGGCCGCACGACAGGAG 3-) was
designed from the genomic contig NT_010498, and the
amplicon sequences (chr16:47,280,772-47,287,772, hg19)
were checked by BLAT against the human sequence in
order to ensure amplification specifity. Ten nanograms
of clone CTD-2027D24 were used as a template. The 7
kb PCR product was run in 1% low-melting agarose and
subsequently purified. All of the BAC/PAC probes were
nick-translation labelled with biotin (Roche, cat N.
11093070910), digoxigenin (Roche, cat N. 11093088910)
or CY3-dUTP (Amersham, cat N.PAS3022), whereas the
PCR product probe was labelled by means of oligoprim-
ing (Prime-It Fluor Fluorescence labelling kit, Strata-
gene, cat. N. 300380). All of the FISH probes were used
following the protocols of Lichter and Cremer with
minor modifications [35]. Each of the BAC clones was
previously tested on chromosomal spreads from normal
controls, and only those giving a signal on the chromo-
somal band indicated by the Genome Browser (UCSC)
were used. The specificity of the probe obtained by
means of long-range PCR was validated by a FISH
experiment that gave a single signal on chromosome
16q11.2. Digital images were obtained using a Leica
DMR epifluorescence microscope (Leica Imaging Sys-
tems Ltd) equipped with a CCD camera (Cohu Inc).
DEAC, FITC, Cy3, and DAPI fluorescence signals were
detected using specific filters. The images were
recorded, pseudocolored, and merged using QFISH soft-
ware (Leica Imaging Systems Ltd), and finally edited
using Adobe Photoshop CS4 (Adobe Systems).
Array comparative genome hybridisation (CGH) analysis
For array CGH analysis genomic DNA was extracted
from proband’s and parent’s whole blood using the
Dneasy Blood & Tissue Kit (Sigma-Aldrich, cat. N.
NA2020) according to the manufacturer’s instructions.
Pooled DNA from the peripheral blood of 10 healthy
donors (Promega, cat. N. G1521), sex-matched to the
samples, was used as a reference. Genome scan was per-
formed by the Human Genome CGH Microarray Kit
244 K (Agilent Technologies, cat. N. G4411B). Briefly, 3
μg of DNA from the test and the normal reference were
processed according to the manufacturer’s protocol.
Images were extracted using Agilent Feature Extraction
software 9.1 and analysed by DNA Analytics 4.0 soft-
ware. A log ratio plot between test and reference
genomic DNA was assigned so that aberrations in test
DNA copy number at a particular locus are observed as
the deviation of the ratio plots from a modal value of 0.
Aberration calls were identified by the ADM-2
algorithm.
X inactivation analysis
The X-inactivation pattern was assessed using the
Humara Androgen Receptor locus and the DXS6673E
locus methylation assay as previously described [36,37].
PCR products were run by capillary electrophoresis and
XCI values determined in heterozygous cases using the
formula previously reported [38]. This formula calcu-
lates the XCI pattern as (d1/u1)/(d1/u1 + d2/u2), where
d1 and d2 represent the two peak areas from the
digested sample and u1 and u2 are the corresponding
areas of the alleles obtained from undigested DNA.
Expression analysis
Briefly, RNA was extracted from the patient and con-
trols lymphoblast cell lines using Trizol (Gibco BRL. cat
N. 15596-018) DNAse-treated (Invitrogene, cat N.
18068-015), and cDNA synthesized using the Supscrip-
tIII Kit (Invitrogen, cat N. 117-52-050) protocol with
gene-specific reverse strand primers.
The investigated genes were SHCBP1, VPS35, ORC6L,
GPT2, DNA JA2, NETO2/BTCL2, ITFG1, ABCC12,
SIAH1, N4BP, CBLN1, ADCY7, BRD7, CYLD, SALL1,
RBL2, HERPUD, and CKLF. The primer pairs designed
for each gene, which spanned coding sequences, are
listed in Additional file 5: Table S3. Quantitative RT-
PCR was performed using the comparative threshold
cycle method of the Syber-Green (SYBR®Green PCR
Master Mix - Applied Biosystem, cat N. 4309155) proto-
col, as described by Livak and Aarskog and Vedeler
[39,40]. The RT-PCR and data analyses were carried out
using an ABI PRISM 7900HT Sequence Detection Sys-
tem (Applied Biosystem). The estimated expression of
all of the genes was computed from three independent
retrotranscriptions obtained from three different RNA
extractions; the threshold cycle number (Ct) values were
obtained from three replicas, and normalised to the
endogenous HGPRT control gene. RNA from three
healthy human controls (one female and two males)
were used as the calibrator sample.
Ct values were determined for all of the PCR reac-
tions, and a comparative Ct method was used to calcu-
late the copy numbers of the expressed transcripts. The
relative quantity of expressed transcript was calculated
as RQ = 2-(ΔΔCt ± standard deviation [SD]) [39,40].
Methylation analysis
The methylation status of the NETO2/BTCL2, SIAH1,
RBL2 and CYLD promoter regions was analysed by
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means of pyrosequencing technology. The bisulfite con-
version of genomic DNA (1 μg) was obtained using the
EZ DNA methylation kit (Zymo Research, cat N.
D5002). After bisulfite treatment, PCR was carried out
in a final volume of 50 μl with 2.5 units of Promega
Go-Taq polymerase (Promega, cat N. M8301). The pri-
mers for modified sequences are summarised in Addi-
tional file 4: Table S3. The PCR conditions were 45
cycles of 95°C for 30 sec, 52°C for 30 sec, and 72°C for
30 sec, followed by 72°C for 5 min; 30 μl of the PCR
product were used for the pyrosequencing assay carried
out using the sequencing primers (Figure 3).
The pyrosequencing reactions were performed in a
PSQ HS 96 System (Biotage, Uppsala, Sweden) by using
Pyro Gold Reagent kits (Qiagene, cat. N. 972804).
Methylation was quantified using Pyro Q-CpG Software
(Biotage), which calculates the ratio of converted C’s
(T’s) to unconverted C’s at each CpG site and expresses
this as a percentage of methylation. To assess the
methylation pattern under normal conditions, we ana-
lysed a control lymphoblastoid cell line and different
normal DNA from peripheral blood lymphocytes.
Chromatin immunoprecipitation assay (ChIP)
Chromatin immunoprecipitation was assayed using the
chromatin immunoprecipitation assay kit and anti-
acetyl-histone H3 (AcH3) (Upstate Biotechnology, cat
N. 06-599), anti-acetyl-histone H4 (AcH4) (Upstate Bio-
technology, cat N. 06-866), anti-di and -trimethyl-his-
tone H3 Lys4, H3DimK4 (Upstate Biotechnology, cat N.
07-030) and H3TrimK4 (Upstate Biotechnology, cat N.
04-745), anti-di and -trimethyl-histone H3Lys 9,
H3DimK9 (Upstate Biotechnology, cat N. 07-441) and
H3TrimK9 (Upstate Biotechnology, cat N. 07-442), and
anti-dimethyl-histone H3 Lys27 (H3DimK27) (Abcam
anti - H3 Trim K27 cat.N. ab6002) antibodies in accor-
dance with the manufacturer’s instructions, with minor
modifications. Chromatin was immunoprecipitated from
2 × 106 lymphoblastoid cells (per antibody) taken from
the patient and control [41].
Quantitative RT-PCR was performed on immunopre-
cipitated chromatin as previously described in order to
verify the quantitative changes in histone modifications
on the VPS35 promoter. The primer sequences specific
for the VPS35, NETO2/BTCL2, SIAH1, PGK1 and HPRT
genes (the last two used as controls) are shown in Addi-
tional file 6: Table S4.
Consent
Written informed consent to the research investigation,
which was approved by the Ethical Clinical Research
Committee of Istituto Auxologico Italiano, was obtained
from the proband’s parents.
Additional material
Additional file 1: Table S1. BAC FISH results.
Additional file 2: Figure S1. Array CGH profile of index case DNA Left
panel) Whole chromosome X array profile. The scatter plot analysis
shows a duplication in Xp22.2 (horizontal shift to the right of 0). Right
panel) Zoomed-in gene view of left panel focussing on a 1.5 Mb
window within Xp22.2 containing the duplication. Each point represents
a single probe. Log2 (ratio) was plotted for all of oligonucleotide probes
on the basis of their chromosome positions. The aberration calls
identified by the ADM-2 algorithm (coloured areas) are shown.
Additional file 3: Figure S2. X chromosome inactivation pattern.
DXS6673E analysis. Electropherograms obtained from undigested and
digested (HhaI and Rsa I enzymes) DNA of mother and patient. Both
samples are heterozygous: patient genotype 1-3 (XCI ratio 82:18), mother
genotype 1-2 (59:41).
Additional file 4: Table S2. Chromatin immunoprecipitation assay
results.
Additional file 5: Table S3. Primers used for quantitative PCR.
Additional file 6: Table S4. Primers used for ChIP and methylation
assay.
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ACTH: Adrenocorticotropin hormone; aCGH: Array Comparative Genomic
Hybridization; CNVs: Copy Number Variants; ChIP: Chromatin Iimmune
Precipitation; EEG: Electroencephalography; FISH: Fluorescence in situ
Hybridization; GVG: Gamma vinyl GABA(gamma aminobutyric acid); i-FISH:
Interphase Fluorescence in situ Hybridization; MRI: Magnetic Resonance
Imaging; NOR: Nucleolar Organization Region; PB: Phenobarbital; PE: Position
Effect; PEV: Position Effect Variegation; QFQ: Q-banding methods using
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